COST
63
5
EXPE
91
3
HOG
33
4
XYL
45
8
PNR
69
4
PPG
60
3
CMI
64
5
WAT
53
6
ISRG
76
2
KMI
69
2
SJM
21
2
DLTR
38
4
ICE
62
3
WHR
64
3
BXP
52
2
NTAP
66
2
MCD
50
-2
IFF
56
3
AKAM
50
7
MU
36
5
COST
63
5
EXPE
91
3
HOG
33
4
XYL
45
8
PNR
69
4
PPG
60
3
CMI
64
5
WAT
53
6
ISRG
76
2
KMI
69
2
SJM
21
2
DLTR
38
4
ICE
62
3
WHR
64
3
BXP
52
2
NTAP
66
2
MCD
50
-2
IFF
56
3
AKAM
50
7
MU
36
5
Financhill
Back

Aclaris Therapeutics 10K Form

Buy
60

ACRS
Aclaris Therapeutics

Last Price:
3.87
Seasonality Move:
46.43%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ACRS News And Ratings

See the #1 stock for the next 7 days that we like better than ACRS

ACRS Financial Statistics

Sales & Book Value

Annual Sales: $31.25M
Cash Flow: $22M
Price / Cash Flow: 0
Annual Sales: $1.82
Price / Book: 2.37

Profitability

EPS (TTM): -0.52000
Net Income (TTM): $-37M
Gross Margin: $13.17M
Return on Equity: -25.72%
Return on Assets: -19.83%

Aclaris Therapeutics Earnings Forecast

Key Aclaris Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for ACRS is 42.14%.
  • The Selling, General & Administrative Expenses for ACRS have been equal to 99.52% of Gross Profit Margin.
  • The Research & Development expenses have been 314.84% of Revenue.
  • The Net Earning history of ACRS is -283.15% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Aclaris Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ACRS
CUSIP: 00461U
Website: aclaristx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.03
Quick Ratio: 6.81

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ACRS Technical Analysis vs Fundamental Analysis

Buy
60
Aclaris Therapeutics (ACRS) is a Buy

Is Aclaris Therapeutics a Buy or a Sell?